Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock Has Consensus Target Price of $37.25 According to Analysts

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $37.25.

Several brokerages recently commented on ZLAB. Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Citigroup increased their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wall Street Zen raised shares of Zai Lab from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Finally, Zacks Research raised shares of Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th.

Insider Buying and Selling at Zai Lab

In related news, Director William Lis sold 8,506 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $25.00, for a total value of $212,650.00. Following the transaction, the director directly owned 41,931 shares of the company’s stock, valued at approximately $1,048,275. This trade represents a 16.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 9,385 shares of company stock worth $235,145. 4.88% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zai Lab

Several institutional investors have recently bought and sold shares of ZLAB. Headlands Technologies LLC raised its holdings in shares of Zai Lab by 142.0% during the second quarter. Headlands Technologies LLC now owns 68,010 shares of the company’s stock valued at $1,292,000 after acquiring an additional 39,901 shares during the last quarter. Seven Fleet Capital Management LP lifted its position in shares of Zai Lab by 74.7% in the second quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock valued at $2,584,000 after acquiring an additional 58,158 shares in the last quarter. WealthPlan Investment Management LLC purchased a new position in shares of Zai Lab in the third quarter valued at approximately $969,000. Finally, Nykredit A S acquired a new stake in shares of Zai Lab in the second quarter worth approximately $79,000. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Stock Performance

Zai Lab stock opened at $25.08 on Friday. Zai Lab has a 12 month low of $15.96 and a 12 month high of $29.77. The business has a 50 day simple moving average of $25.38 and a 200-day simple moving average of $21.73.

Zai Lab (NASDAQ:ZLAB) last announced its earnings results on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative return on equity of 27.43% and a negative net margin of 41.86%. The business had revenue of $106.31 million for the quarter. As a group, research analysts anticipate that Zai Lab will post -2.37 EPS for the current fiscal year.

Zai Lab Company Profile

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.